Skip to main content

Belen Garcia Prats

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Belen Garcia Prats

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences and I obtained in 2020 a MSc in Molecular Biotechnology. Hence, I am passionate about biomedical research areas such as pharmacology and toxicology, cancer biology and molecular techniques.
My previous experience encompasses working in a clinical laboratory, being in charge of the realization of biochemical and immunological analysis on clinical simples. In addition, I was parto f a basic research group, where I worked with cell cultures for the study of type 2 diabetes mellitus pathogenesis.
Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR. I have obtained the laboratory animals handling accreditation, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

Projects

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo.

IP: Joaquin Seras Franzoso
Collaborators: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI22/01301
Duration: 01/01/2023 - 31/12/2025

Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO)

IP: Ibane Abasolo Olaortua
Collaborators: Joaquin Seras Franzoso, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: EUROPEAN COMMISSION
Funding: 568847.5
Reference: EVO-NANO_H2020FETOPEN2017
Duration: 01/10/2018 - 31/03/2022

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Rafael Parra López

Rafael Parra López

Head of group
Transfusional Medicine
Read more
Paredes Deiros, Carolina

Paredes Deiros, Carolina

Research technician
Stroke research
Read more
Alperi Garcia, Sofia

Alperi Garcia, Sofia

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Camacho Arteaga, Lina Fernanda

Camacho Arteaga, Lina Fernanda

Research technician
Clinical Pharmacology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.